Clinical trial
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During…
NCT00448864 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Terminated
Key facts
| NCT number | NCT00448864 |
|---|---|
| Title | Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement |
| Official title | KALAHARI-1: Kallikrein Antagonist (DX-88 [Ecallantide]) Effect on Blood Loss Associated With Heart Surgery Requiring Institution of Bypass |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Blood Loss, Surgical |
| Intervention type | Drug |
| Interventions | Ecallantide, Placebo |
| Enrollment | 75 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Mar 19, 2007 |
| Last update posted | Jun 25, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: